HighTower Advisors
RCKT icon

HighTower Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

HighTower Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,700
Closed -$138K – 3935
2025
Q1 		$138K Buy
20,700
+2,952
+17% +$29.2K ﹤0.01% 3290
2024
Q4 		$223K Sell
17,748
-1,073
-6% -$16.2K ﹤0.01% 3119
2024
Q3 		$346K Sell
18,821
-5,556
-23% -$114K ﹤0.01% 2709
2024
Q2 		$525K Buy
24,377
+165
+0.7% +$3.79K ﹤0.01% 2289
2024
Q1 		$653K Sell
24,212
-3,504
-13% -$99.5K ﹤0.01% 2087
2023
Q4 		$831K Sell
27,716
-1,000
-3% -$22.1K ﹤0.01% 1942
2023
Q3 		$589K Sell
28,716
-1,613
-5% -$29.3K ﹤0.01% 2117
2023
Q2 		$603K Sell
30,329
-117,400
-79% -$2.37M ﹤0.01% 2061
2023
Q1 		$2.53M Buy
147,729
+55,175
+60% +$1.08M 0.01% 1154
2022
Q4 		$1.81M Buy
92,554
+65,107
+237% +$1.2M ﹤0.01% 1344
2022
Q3 		$439K Sell
27,447
-2,653
-9% -$41.4K ﹤0.01% 2104
2022
Q2 		$416K Buy
30,100
+9,100
+43% +$108K ﹤0.01% 2158
2022
Q1 		$336K Buy
21,000
+4,879
+30% +$84.3K ﹤0.01% 2439
2021
Q4 		$351K Buy
16,121
+761
+5% +$20.8K ﹤0.01% 2384
2021
Q3 		$460K Sell
15,360
-800
-5% -$29.1K ﹤0.01% 2102
2021
Q2 		$716K Sell
16,160
-790
-5% -$34.3K ﹤0.01% 1839
2021
Q1 		$750K Sell
16,950
-1,283
-7% -$70.4K ﹤0.01% 1735
2020
Q4 		$1M Sell
18,233
-4,467
-20% -$163K ﹤0.01% 1260
2020
Q3 		$518K Buy
22,700
+800
+4% +$19.7K ﹤0.01% 1550
2020
Q2 		$458K Sell
21,900
-3,550
-14% -$64K ﹤0.01% 1512
2020
Q1 		$356K Buy
25,450
+1,250
+5% +$24.8K ﹤0.01% 1480
2019
Q4 		$552K Buy
+24,200
New +$404K ﹤0.01% 1404
2019
Q3 		– Sell
-10,000
Closed -$151K – 2516
2019
Q2 		$151K Hold
10,000
– – ﹤0.01% 2105
2019
Q1 		$176K Buy
+10,000
New +$158K ﹤0.01% 1981
2018
Q3 		– Sell
-21,344
Closed -$422K – 2397
2018
Q2 		$422K Buy
+21,344
New +$404K ﹤0.01% 1524

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

HighTower Advisors's RCKT Position: Q2 2025 in Review

HighTower Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 20,700 shares — an estimated $138K sold.

HighTower Advisors first reported a position in RCKT in Q2 2018 and held it in 25 quarters. The position peaked at $2.53M in Q1 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • HighTower Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • HighTower Advisors sold 20,700 Rocket Pharmaceuticals shares in Q2 2025, an estimated $138K.
  • HighTower Advisors first reported a position in Rocket Pharmaceuticals in Q2 2018 and held it in 25 quarters.
  • HighTower Advisors's Rocket Pharmaceuticals position peaked at $2.53M in Q1 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.